352 related articles for article (PubMed ID: 16166939)
1. Neoadjuvant induction chemotherapy.
Schwartz G
Minerva Ginecol; 2005 Jun; 57(3):327-48. PubMed ID: 16166939
[TBL] [Abstract][Full Text] [Related]
2. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
[TBL] [Abstract][Full Text] [Related]
3. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
[TBL] [Abstract][Full Text] [Related]
4. Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature.
Caliskan M; Gatti G; Sosnovskikh I; Rotmensz N; Botteri E; Musmeci S; Rosali dos Santos G; Viale G; Luini A
Breast Cancer Res Treat; 2008 Dec; 112(3):513-21. PubMed ID: 18240020
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy in breast cancer.
Charfare H; Limongelli S; Purushotham AD
Br J Surg; 2005 Jan; 92(1):14-23. PubMed ID: 15635596
[TBL] [Abstract][Full Text] [Related]
6. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer.
Rouzier R; Pusztai L; Garbay JR; Delaloge S; Hunt KK; Hortobagyi GN; Berry D; Kuerer HM
Cancer; 2006 Oct; 107(7):1459-66. PubMed ID: 16948128
[TBL] [Abstract][Full Text] [Related]
8. Upstaging and improved survival of early breast cancer patients after implementation of sentinel node biopsy for axillary staging.
Vanderveen KA; Schneider PD; Khatri VP; Goodnight JE; Bold RJ
Ann Surg Oncol; 2006 Nov; 13(11):1450-6. PubMed ID: 17009150
[TBL] [Abstract][Full Text] [Related]
9. Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast.
Schwartz GF; Meltzer AJ; Lucarelli EA; Cantor JP; Curcillo PG
J Am Coll Surg; 2005 Sep; 201(3):327-34. PubMed ID: 16125064
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507
[TBL] [Abstract][Full Text] [Related]
11. Preoperative (neoadjuvant) systemic treatment of breast cancer.
Kaufmann M; von Minckwitz G; Rody A
Breast; 2005 Dec; 14(6):576-81. PubMed ID: 16199160
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status.
Piper GL; Patel NA; Patel JA; Malay MB; Julian TB
Am Surg; 2004 Dec; 70(12):1103-6. PubMed ID: 15663054
[TBL] [Abstract][Full Text] [Related]
13. Primary systemic therapy of breast cancer.
Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH
Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237
[TBL] [Abstract][Full Text] [Related]
14. The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer.
Clouth B; Chandrasekharan S; Inwang R; Smith S; Davidson N; Sauven P
Eur J Surg Oncol; 2007 Oct; 33(8):961-6. PubMed ID: 17215100
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant systemic therapy and the surgical management of breast cancer.
Waljee JF; Newman LA
Surg Clin North Am; 2007 Apr; 87(2):399-415, ix. PubMed ID: 17498534
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
17. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
[TBL] [Abstract][Full Text] [Related]
18. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.
Palesty JA; Foster JM; Hurd TC; Watroba N; Rezaishiraz H; Edge SB
J Surg Oncol; 2006 Feb; 93(2):129-32. PubMed ID: 16425295
[TBL] [Abstract][Full Text] [Related]
19. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
20. Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy.
Menard JP; Extra JM; Jacquemier J; Buttarelli M; Lambaudie E; Bannier M; Brenot Rossi I; Houvenaeghel G
Eur J Surg Oncol; 2009 Sep; 35(9):916-20. PubMed ID: 19157769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]